However, screening with a PSA test alone cannot distinguish between clinically significant or indolent prostate cancer, which can result in unnecessary prostate biopsies, overtreatment (with potentially life changing side effects of incontinence and erectile dysfunction), and psychological burden [35]. Here, KLK3 is linked to prostate carcinoma.